Low hdl in elective hernia surgery

1. A PROSPECTIVE STUDY OF A COMMONLY
OVERLOOKED CAUSE OF SURGICAL SITE INFECTION
– LOW HDL IN ELECTIVE HERNIA SURGERY
Dr Akshata Hanamshetti
JR 1 General Surgery
GUIDE:
Dr VV Kanase

2. Introduction
• SSI is the infection following surgery at surgical incision that occurs within
30 days after the surgery.
• responsible for an increased economic burden to health care system
including additional postoperative hospital duration and cost, increases
morbidity to the patient
• Cholesterol acts as the precursor of five major classes of steroid hormones
responsible for stimulating cascade of immune system and complement
pathway.
• cholesterol also plays a major role in, maintenance of membrane fluidity,
cell signaling, biosynthesis of steroid hormones and also forms integral part
of cell membrane.

3. AIM:
• To evaluate association between low HDL level & risk of Surgical Site
Infection.

4. OBJECTIVES:
• To evaluate HDL level in elective hernia surgical patients.
• To study low HDL level association with Surgical Site Infection.

5. Study Design
• Type Of Study: prospective cohort study
INCLUSION CRITERIA:
• Patients of both sexes.
• All patient posted for elective hernia surgery.
EXCLUSION CRITERIA:
• Contaminated surgeries
• Patients with comorbidities like diabetes mellitus, malignancy, end stage liver
disease, immune compromised state.
• Patient undergoing chemotherapy & radiotherapy

6. Methodology
Demographics and history
collection from patient
Preparation of patient for surgery (NBM
from 12 AM of day of surgery)
Blood sample in fasting for HDL
Categorization of HDL
Low: <40 Normal: 40-60 High: >60
Surgery
Evaluation Of Surgical Site
on DAY 1,7,30
Comparison Of Results

7. Sample Size:
𝑁 =
𝑍
1−
𝛼
2
2
𝑝 1 − 𝑝
ƛ2
𝑍1−
𝛼
2
2
= (1.96)2 = 3.8416
P= 0.33
ƛ= 0.1 (precision at 10%)
N=
3.8419 𝑋 0.33 𝑋 0.67
0.01
N= 85

8. KRISHNA INSTITUTE OF MEDICAL SCIENCES, KARAD.
Study Title: “A PROSPECTIVE STUDY OF A COMMONLY OVERLOOKED CAUSE OF SURGICAL SITE
INFECTION – LOW HDL IN ELECTIVE HERNIA SURGERY”
Informed Written Consent Form
• I confirm that I have read & understood the information in the patient information sheet. The
purpose of this study has been explained to me in details along with advantages & disadvantages
of being part of the study program, to ask questions & here by consent to participation in the
study outlined above.
• I understand that the decision to take part in the study is completely voluntary and I am aware
that I can choose to withdraw from the study at any point of time.
• I understand that confidentiality of information will be maintained. I also understand that the
result of the study may be given in the scientific publications or journals without revealing the
identity of the participants.
• I understand the possible risks involved in the study.
• My signature on this form signifies that I have willingly decided to participate after understanding
the above information.
Name and age of patient:
Signature/Left Thumb Impression of patient: Name and signature of witness:
Name and signature of the Doctor:
Date:

9. • क
ृ ष्णा इन्स्टिट्यूट ऑफ मेडिकल सायन्सेस, कराि.
अभ्यासाचे शीर्षक:
प्रीऑपेटिव्ह एचडीएल पातळी एसएसआयच्या वाढीव जोखमीशी संबंटित आहे की नाही याचे मूल्ांकन करण्यासाठी.
सूटचत लेखी संमती फॉमष
1) मी पुष्टी करतो की मी रूग्ण माटहती पत्रकातील माटहती वाचली आटि समजली आहे. या अभ्यासाचा उद्देश मला अभ्यास कायषक्रमाचा भाग होण्याचे फायदे आटि तोिे, प्रश्न
टवचारण्यासाठी आटि वर विषन क
े लेल्ा अभ्यासात सहभागी होण्याच्या संमतीने येथे तशीलवार स्पष्ट क
े ले आहे.
२) मला समजते की अभ्यासात भाग घेण्याचा टनिषय पूिषपिे ऐच्छिक आहे आटि मला माटहती आहे की मी कोित्याही वेळी अभ्यासातून माघार घेिे टनवड
ू शकतो.
3) मला समजते की माटहतीची गोपनीयता राखली जाईल. मला हे देखील समजले आहे की अभ्यासचे पररिाम सहभागीची ओळख न उघडता वैज्ञाटनक प्रकाशने टक
ं वा
जनषल्समध्ये टदले जाऊ शकतात.
4) मा अभ्यासातील संभाव्य िोक
े समजतात,
5) या फॉमषवर माझी स्वाक्षरी सूटचत की वरील माटहती समजून घेतल्ानंतर मी स्वेिे ने सहभागी होण्याचा टनिषय घेतला आहे.
रुग्णाचे नाव आटि वयः
रुग्णाची स्वाक्षरी/डाव्या अंगठ्याचा ठसा
साक्षीदाराचे नाव आटि स्वाक्षरी
डॉक्टरांचे नाव आटि स्वाक्षरी : तारीख :

10. BIBLIOGRAPHY
• Howard.J.R., „Surgical infections‟ Principles of surgery vol. I edtd by Schwartz published by Mc Grawhill, inc 143-75
• Sawyer Robert .G., and Timothy L. pruett, "Wound Infections".Surgical Clinics of North America, 1994, 74; 519 –36
• Dellinger.E.P & Ehrenkranz N.J. „Surgical Infections‟ In Hospital infections 4th edn., edited by J.V.Bennett & Brachnan.P.S. Lippincott Raven publishers, Philadelphia, 1998 571-86.
• Hunt K.T., Reid.V.Muller, „Inflammation, Infection & antibiotics Chapter 8 in Medical Management of the surgical patient. Edtd., by Michaiel Lubig et al, 3rd edn., J.Blippincott co.,
Philadelphia.
• Gaynes.R.P. and Solomon.S., „Improving hospital aquired infection rates; the CDCexperience‟. Jt.Comm.J.Qual Improv. 1996 Jul:, 22 (7); 457-67.
• Roy Marie- Claude, et al, " Does the CDC NNIS Systeln Risk Index Stratify patients undergoing Cardiothoracic Operations by their Risk of SSP" Infection control and Hospital
Epidemiology, 2000 Mar: 21 (3): 186-90.
• Eickhoff.C.T.,Antibiotics & Nosocomial infections‟ Hospital infections, 4th edn, edited by John.r.Bennett & Philip.S.Brachnan. Lippincott-Raven publishers:1998:201-14.
• Ad hHoc committee on Trauma, Division of Medical Sciences, National Academy of sciences, National Research Council 'Post operative wound infections. The influence of ultraviolet
irradiation of the operating room and of various other factors'. Ann surg 1964; 160 (Supp 13); 1-32.
• Hunt K.T., Reid.V.Muller, „Inflammation, Infection & antibiotics Chapter 8 in Medical Management of the surgical patient. Edtd., by Michaiel Lubig et al, 3rd edn., J.Blippincott co.,
Philadelphia
• Olson M.M.,James. T.Lee 'Continuous, 10-year wound Infection Surveillance; results, advantages and unanswered questions' Arch Surg. 1990: 794-803.
• Nichols Ronald lee "Post Operative wound infections" The New England Journal of Medicine, 1982;307: 1701-02
• D. L. Dragnov and B. N. La Du, “Pharmacogenetics of paraoxonases: a brief review,” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 369, no. 1, pp. 78–88, 2004.
• A. J. Luis, “Atherosclerosis,” Nature, vol. 407, no. 6801, pp. 233– 241, 2000.
• D. M. Shih, L. Gu, Y. R. Xia et al., “Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis,” Nature, vol. 394, no. 6690, pp. 284–287, 1998.
• M. Navab, G. M. Ananthramaiah, S. T. Reddy et al., “The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL,” Journal of Lipid Research, vol. 45, no. 6, pp.
993–1007, 2004.

11. THANK YOU